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A B S T R A C T
The aim of this paper is identification of regulatory sequences downstream of –1683 base pairs (bp) in the rat Col1a1
promoter important for expression in osteoblasts. Previous findings suggest that a rat Col1a1 gene fragment extending
from –1719 to +115 bp linked to the chloramphenicol acetyl transferase (CAT) reporter gene (ColCAT1719) is highly and
selectively expressed in osteoblasts. Three internal deletions within the ColCAT1719 construct were generated and stably
transfected into ROS 17/2.8 cells. CAT activity was measured in cell extracts. An internal deletion of ColCAT1719 from
–1637 to –504 bp caused an almost complete loss of CAT activity, whereas deletions of –1284 to –905 bp and –1284 to –451
bp had little effect on CAT activity. We hypothesized that removal of a Runx2/Cbfa1 consensus site at –1376 bp may have
caused the loss of activity produced by the –1637 to –504 bp deletion. To test this hypothesis, we produced a more re-
stricted internal deletion of ColCAT1719 from –1418 to –1284 bp, which removes this site. This deletion did not affect
promoter activity. Our results suggest that the Runx2 site at –1376 bp by itself does not influence Col1719 promoter activ-
ity. Future studies will focus on the region between –1637 to 1418 bp, which contains several potentially interesting tran-
scription factor binding sites.
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Introduction
The protein content of bone is composed of approxi-
mately 95% type I collagen, with the remainder contrib-
uted by a variety of noncollagen proteins and proteo-
glycans. Type I collagen serves as the essential structural
protein of the skeleton, imparting stability and strength
to bone tissue. Each type I collagen molecule is a triple
helix containing two identical '11 chains and one '21
chain, which are encoded by two distinct genes1. A high
level of expression of type I collagen is a phenotypic hall-
mark of differentiated osteoblasts. Type I collagen syn-
thesis in osteoblasts is regulated by a variety of hor-
mones and transcription factors. Hormones such as
glucocorticoids2, 1.25-dihydroxyvitamin D3
3, parathyroid
hormone4–5 and fibroblast growth factor6–7 inhibit type 1
collagen synthesis in vitro, whereas insulin like growth
factor-I8 and transforming growth factor-ß9 increase type
I collagen synthesis.
Our laboratories have previously developed transgen-
ic mice that harboring Col1a1 promoters linked to the
chloramphenicol acetyl transferase (CAT) reporter. The
parental Col1a1-CAT construct containing a 3.6 kb re-
gion of the Col1a1 gene from –3591 to +115 bp was
termed ColCAT3.610. Serial 5’ deletions of ColCAT3.6
were generated to map elements that mediate tissue spe-
cific expression. CAT activity in calvariae remained high
in constructs deleted to –2295, –1997, –1794, –1719, and
–1683 bp11–13, while further deletion to –1670 bp com-
pletely eliminated activity. These data strongly indicated
that transcriptional regulatory elements directing ex-
pression in osteoblasts were located between –1683 and
–1670 bp14. Site directed mutation of a TAAT motif
within this region showed that it was necessary for high
CAT activity in calvariae14.
The goal of the present study was to identify elements
downstream of –1670 bp, which may govern the expres-
sion of the rat Col1a1 promoter in osteoblasts. Internal
deletions of ColCAT1719 were generated and stably
transfected into ROS 17/2.8 cells. A deletion of sequences
between –1637 and –1284 bp significantly reduced pro-
moter activity. Interestingly, within that region is a
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Runx2 site at –1376 bp. To define its involvement in pro-
moter activity, a more restricted internal deletion encom-
passing this site was produced. This deletion, however,
did not affect promoter activity suggesting that the site is
not necessary for expression in osteoblasts.
Materials and Methods
Materials
The sources for material used in this study were as
follows: F-12 nutrient mixture, Lipofectamine reagent,
oligonucleotides (Invitrogen, Carlsbad, CA, USA); Pflf 1,
Stu 1, Aat 2, Bsu 36 1, Blp 1 (New England Biolabs Inc.,
Beverly, MA USA); Hind 3, Xba 1, Pst 1 enzymes Invit-
rogen, Carlsbad, CA, USA; 3Hacetyl coenzyme A, 200
mCi/mmol (NEN Life Science Products Inc, Boston, MA,
USA); tissue culture plates (Costar, Cambridge, MA,
USA); reporter lysis buffer (Promega, Madison,WI, USA);
Econoflour-2 (PerkinElmer Life and Analytical Sciences,
Boston, MA, USA).
DNA constructs
The generation of ColCAT1719, which has sequences
of the rat Col1a1 promoter between –1719 and +116 bp
fused to the CAT reporter gene and the SV40 small T an-
tigen splice site and polyadenylation signal from pSVCAT,
has been previously described13. Four different internal
deletions of ColCAT1719 were generated (Figure 1). To
produce (379, ColCAT 1719 was digested with Pflf 1
(–1284 bp), blunt-ended, digested with Stu 1 (–905 bp)
and ligated. The second deletion, (833, was produced us-
ing a similar approach as for (379 except that Stu 1 was
replaced by Bsu 36 1 (–451 bp). The third deletion,
(1133, was produced using Bpu 1, which has two restric-
tion sites (–1637 bp, –504 bp) within ColCAT1719. For
the fourth deletion, (134, a Hind 3/Xba 1 digested frag-
ment of ColCAT1719 containing 1830 bp, was subcloned
in Litmus 28. Subsequently, the DNA was digested with
Aat 2 (–1418 bp) and Pflf1 (–1284 bp), blunt-ended, li-
gated, and digested with Hind 3/Xba 1 to reinsert this
truncated promoter into Hind 3/Xba 1 digested
ColCAT1719.
Stable transfection
ROS 17/2.8 cells were maintained in F-12 medium
supplemented with 10% of non heat- inactivated fetal bo-
vine serum (New England Biolabs inc, Beverly, MA,
USA), 100 U/ml penicillin and 50 g/ml streptomycin
(basal medium) at 37 )C in a humidified atmosphere of
5% CO2. On the day prior to transfection, 2 * 10
5 cells
were plated in each 35 mm dish; 18 h later, the cells were
rinsed twice with phosphate buffered saline (PBS) and
incubated for 5 h in serum- and antibiotic-free F-12 me-
dium containing 1 g of a Col1a1-CAT plasmid, 0.1 g of
TK-Hygro plasmid, which carries the resistance gene for
hygromycin, and 8 l of Lipofectamine reagent. After 5 h,
medium was replaced and the cells were cultured in basal
medium for 72 h. The cells were then passaged and
placed under selection with 200 g /ml of hygromycin.
Resistant clones were pooled, grown to confluence, and
harvested for measurement of CAT activity.
Measurement of CAT Activity
Cells were scraped into 1 ml of CAT scraping buffer
(0.04 M Tris-HCL, pH 7.4, 1 mM EDTA, 0.15 M NaCl),
rinsed twice with PBS, pH 7.4, re-suspended and centri-
fuged for 5 min. Pellets were re-suspended in buffer con-
taining 0.25 M Tris-HCl (pH 7.8) and 0.5 % Triton X-100
and subjected to three cycles of freezing on dry ice, each
followed by thawing at 37 )C. The extracts were heated
at 65 )C for 15–20 min to inactivate endogenous deace-
tylases and centrifuged at 14,000 * g for 3 min. A fluor
diffusion assay was used to measure CAT activity in the
extracts as previously described5,14. Up to 10 l of extract
were added to 200 l of a reaction mixture containing 1
mM chloramphenicol, 0.2 µCi 3Hacetyl coenzyme A and
0.025 M Tris-HCl, pH 7.8, in a 7 ml scintillation vial. The
aqueous phase reaction mix was overlaid with 5 ml tolu-
ene or Econoflour-2 based scintillation fluid. The vials
were incubated at 37 )C for up to 5 h and counted every
hour. CAT activity was calculated as described previo-
usly5 and was normalized to protein in the extract, as
measured with the indicator bicinchoninic acid15.
Statistics
Data were analyzed using the One-Sample Kolmo-
gorov-Smirnov Test and t-test for Equality of Means.
Results
We stably transfected ROS17/2.8 cells with four con-
structs having different internal deletions of ColCAT-
1719 (Figure 1). Transfected cells were analysed at 2 to 3
days post confluence. Deletion of the sequences between
–1284 to –905 bp ((379), and –1284 to –451 bp ((833),
did not significantly affect CAT activity. However, a dele-
tion from –1637 to –504 bp ((1133) reduced CAT activity
to nearly undetectable levels (Figure 2). These data sug-
gested that a 350 bp region between –1637 to –1284 bp
was required for ColCAT1719 expression. A computer
search of this sequence revealed a consensus binding site









Fig. 1. Internal deletions of ColCAT1719. Constructs were named
by the number of deleted base pairs:  379,  833,  1133 and
  The Runx2 binding at –1376 bp is shown.
at –1376 bp for the transcription factor Runx2 (Figure 1).
To address the possible role of Runx2 in ColCAT1719 ex-
pression, we generated a more restricted internal dele-
tion of 134 bp between –1418 and –1284 bp ((134), which
included this Runx2 site. There was no significant effect
of this deletion on promoter activity (Figure 2). In addi-
tion, a specific mutation of the Runx2 also did not inhibit
activity (data not shown). Taken together, these data
suggest that the region between –1637 and –1418 bp is
likely to contain one or more positive transcriptional ele-
ments.
Discussion
In the current study, we generated four internal dele-
tions of ColCAT1719 and tested the activity of these con-
structs in stably transfected ROS17/2.8 osteoblastic os-
teosarcoma cells16–17. These cells express bone markers
such as type I collagen, osteocalcin, alkaline phosphata-
se, osteopontin, bone sialoprotein, have receptors for
parathyroid hormone and 1.25-dihydroxyvitamin D3, and
produce mineralized tumors. Therefore, we have used
them previously10 and in the present study as a model for
examining Col1a1 promoter activity in cells of the osteo-
blast lineage.
Our deletion studies of the Col1a1 promoter identi-
fied a region between –1637 and –1284 bp that is neces-
sary for the maximal promoter activity of ColCAT1719,
leading us to speculate that this 350 bp region contained
important regulatory elements required for promoter ac-
tivity. A preliminary search of the 350 bp implicated by
these internal deletion experiments revealed a Runx2
binding site at –1376 bp.
Runx2 plays a critical role in osteoblastic differentia-
tion and bone formation18–20. Knockout of the Runx2
gene in mice results in a complete loss of osteoblast dif-
ferentiation. Mutations in the Runx2 gene cause skeletal
abnormalities and defective bone formation in cleido-
cranial dysplasia (CCD), an autosomal dominant disor-
der in humans and mice20–22. Overexpression of Runx2
regulates osteoblast specific gene expression in vitro24
and is able to induce osteoblastic markers in non-osteo-
blastic cells25. Two isoforms of the Runx2 gene have been
identified that differ in their N-terminal sequence26.
Runx2 mRNA is expressed in primary bone cells and nu-
merous osteoblastic cell line27. The precise role of Runx2
on Col1a1 expression is not completely understood. Stu-
dies have shown both stimulatory24–28 and inhibitory30 ef-
fects of Runx2 on Col1a1 expression. Therefore, we hy-
pothesized that deletion of a Runx2 site could have
contributed to loss of activity seen with the (1133 dele-
tion. The (134 deletion between –1418 and –1284 bp in-
cluded the Runx2 binding site (Figure 1) at –1376 bp. We
predicted that the deletion would abolish promoter activ-
ity. However, the deletion did not affect CAT activity in
stably transfected ROS17/2.8 cells. In addition, a specific
site directed mutation of this Runx2 binding site did not
inhibit activity of the construct. These results are in con-
trast to the studies of Kern et al28, who found that a muta-
tion in the homologous site in the mouse Col1a1 promoter
caused an approximately 2-fold decrease in promoter ac-
tivity. We do not have a conclusive explanation for this
discrepancy; however, one possiblity is that the mouse
Col1a1 promoter may have a different requirement for
this promoter element than the rat promoter.
Our studies do not eliminate the possibility that Runx2
binding sites play an important role in regulation of
ColCAT1719, because a computer search of the region
downstream of –1376 bp revealed four additional Runx2
sites. Future studies involving mutation of these sites,
both singly and in combination, will reveal the role of
Runx2 in regulating Col1a1 promoter expression.
Previously, it has been shown that a 117 bp sequence
of the mouse Col1a1 promoter between –1656 and –1540
bp is the minimal sequence able to induce high levels of
expression in osteoblasts29–30. This sequence was further
divided into several sub-segments having different func-
tions; a region between –1656 and –1628 bp is required
for specific expression in osteoblasts, while a sequence
from –1575 to –1540 bp is required for high expression in
osteoblasts. Alignment of the mouse and rat sequence
within this region reveals a 55 bp overlap between the se-
quence identified by Rossert et al30 and the sequnce iden-
tified by our deletion studies, which extends from –1637
to –1582 bp in the rat sequence. Examination of this se-
quence using the TESS – transcription factor site search
web site31 revealed several potential transcription factor
binding sites with high probability of relevance. Analysis
of the significance of these sites by mutation should
prove informative in identifying regulatory elements in
the Col1a1 promoter.





Fig. 2. Effect of internal deletions on CAT activity in stably trans-
fected ROS17/2.8 cells. Each value is the X±SD of 6–12 samples.
*Different from ColCAT1719, p<0.01. Cpm/g – counts per
minute per microgram.
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ANALIZA UNUTRA[NJIH DELECIJA DIJELOVA [TAKORSKOG KOLAGENSKOG
PROMOTORA U TRANSFEKTIRANIM ROS17/2.8 STANICAMA
S A @ E T A K
Cilj ovog rada je identifikacija regulatornih sekvenci nizvodno od –1683 parova baza u {takorskom kolagenskom
promotoru va`nih za ekspresiju u osteoblastima. Prethodna istra`ivanja su pokazala da je genski fragment {takorskog
kolagenskog promotora koji se nalazi izme|u –1719 i +115 parova baza (pb) povezan sa CAT (kloramfenikol acetil
transferaza) reporter genom, dakle ColCAT1719, specifi~no i selektivno izra`en u osteoblastima. Tri unutra{nje de-
lecije ColCAT1719 konstrukta su napravljene i stabilno transfektirane u ROS17/2.8 stanice. U ekstraktima stanica
mjerena je CAT aktivnost: Unutra{nja delecija ColCAT1719 konstrukta od –1637 do –504 pb uzrokovala je gotovo pot-
puni gubitak CAT aktivnosti, dok su delecije od –1284 do –905 i od –1284 do –451 pb imale mali efekt na CAT aktivnost.
Pretpostavili smo da je odstranjenje Runx2-Cbfa1 konsenzus mjesta na –1376 pb uzrokovalo gubitak aktivnosti pro-
izveden sa delecijom od –1637 do –504 pb. Za testiranje ove pretpostavke napravili smo jo{ specifi~niju unutra{nju
deleciju ColCAT1719 konstrukta od –1418 do –1284 pb, kojom se odstranjuje ovo mjesto. Ova delecija nije imala u~inka
na promotorsku aktivnost. Na{i rezultati pokazuju da Runx2 mjesto na –1376 pb samo po sebi nema utjecaja na ak-
tivnost Col1719 promotora. Budu}a istra`ivanja }e se usredoto~iti na podru~je izme|u –1637 i 1418 pb, koje sadr`i
nekoliko potencijalno zanimljivih veznih mjesta za transkripcijske faktore.
A. Ivko{i} et al.: Col1a1 Promoter Activity in Osteoblasts, Coll. Antropol. 30 (2006) 2: 401–404
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